From discovery to clinical development the field of protein degradation is booming with excitement, with a whole host of investments and new companies joining the effort to successfully degrade unwanted or undrugged targets with key roles in a broad range of diseases from oncology to CNS, through to autoimmune.
Despite this, key challenges remain to rapidly and successfully discover novel and underexploited Ubiquitin E3 ligases. It is now critical that we fully understand the structure and function of E3’s, accelerate ligand screening with new and improved tools, making this process less lengthy and risky for biopharma.
The 2nd Ligase Targeting Drug Development Summit returns virtually with new insight and data from pioneers in the field to delve deep into ligase biology, assays to investigate functions as well as screening tools for optimum ligand identification and validation.
This forum will provide an unrivaled meeting-point for industry leaders, in order to strategically accelerate and de-risk the process of identifying, validating, and therapeutically leveraging cell and tissue specific Ubiquitin E3 ligases for degradation or modulation of targets of interest.